US EditionAs competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth
BridgeBio's sales of its new transthyretin amyloid cardiomyopathy drug almost doubled this quarter. But that still wasn't good enough for investors in what is becoming one of biotech's most competitive new categories. Attruby
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
